Mostrar el registro sencillo del ítem

dc.contributor.authorBernardo Ordiz, David
dc.contributor.authorGarrote Adrados, José Antonio 
dc.contributor.authorNadal, I.
dc.contributor.authorLeón, Alberto José
dc.contributor.authorCalvo Romero, María del Carmen
dc.contributor.authorFernández Salazar, Luis Ignacio 
dc.contributor.authorBlanco Quirós, Alfredo
dc.contributor.authorSanz, Y.
dc.contributor.authorArranz Sanz, Eduardo 
dc.date.accessioned2014-02-27T09:26:13Z
dc.date.available2014-02-27T09:26:13Z
dc.date.issued2009
dc.identifier.citationGut, 2009, vol. 000 No 000es
dc.identifier.urihttp://uvadoc.uva.es/handle/10324/4436
dc.description.abstractProlyl-endopeptidase supplementation has been proposed to favour gliadin degradation as an alternative treatment for coeliac disease (CD), although the real usefulness of this therapy in vivo is still under discussion. 1 However, our data point to alternative treatments aiming to modify the intestinal microbiota in patients with CD by the use of probiotics and/or prebiotics. We propose that the induction of gliadin proteolysis in the human gut might not be the solution but the origin of CD.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherInstituto de Biología y Genética Moleculares
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectEnfermedad celíacaes
dc.subjectGliadinaes
dc.subjectIntestinos - Enfermedadeses
dc.titleIs it true coeliacs do not digest gliadin ?. Degradation pattern of gliadin in coeliac disease small intestinal mucosaes
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.publicationfirstpage1es
dc.identifier.publicationissue0es
dc.identifier.publicationlastpage2es
dc.identifier.publicationtitleGutes
dc.identifier.publicationvolume0es
dc.peerreviewedSIes
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem